Recent News

ASCO 2021: Time-Limited Use of Aspacytarabine for Patients With AML Who Are Unfit for Chemotherapy

EHA2021: Post Hoc Analysis of Oral Azacitidine in AML From QUAZAR AML-001 Trial

ASCO 2021: Novel FLT3 Inhibitor Under Study in Resistant AML

ASCO 2021: Interim Analysis of Phase II Trial of Olutasidenib in IDH1-Mutant AML

Australian Researchers Use Novel Work Utility Measure to Assess Productivity Impact of AML

Trousseau Syndrome and AML: Case Report

Venetoclax-Based Therapy and Azole Antifungals in AML: Effects on Blood Cell Counts

Quizartinib Combinations Under Study in FLT3-ITD–Mutated AML

Whole-Genome Sequencing for Genetic Profiling in Myeloid Cancers

Pilot Study in AML: Can Biomarkers Predict Chemotherapy-Related Infection?

Dactinomycin Under Study in Management of Resistant NPM1-Mutated AML

Have Outcomes in AML Improved Over the Past 40 Years?

CPX-351 for High-Risk AML: Phase III Post Hoc Analysis

AACR 2021: Daratumumab Plus Venetoclax Under Study in AML

Chemotherapy Intensity, MRD Status, and Outcomes in AML

AACR 2021: Is SIRT5 Enzyme Potential Therapeutic Target in AML?

Optimal Number of Chemotherapy Courses for Younger Patients With AML

Testing for Germline Mutations in Elderly Patients With AML

Green Tea Treatment in Elderly Patients With Myelodysplasia-Related AML

Comparison of Hypomethylating Agent Plus Venetoclax With CPX-351 in Secondary AML

Predicting Response to Venetoclax Combination Therapy in Resistant AML

Revised Label Approved by FDA for Daunorubicin/Cytarabine Combination for AML

Case Report: Central Diabetes Insipidus and AML

Using Existing Drugs to Treat Unique Subtype of NPM1-Mutated AML

Phase II French Trial of Eprenetapopt Plus Azacitidine in AML

Prognostic Impact of IDH Mutational Status in AML After HSCT

Can Fractionated Myeloablative Busulfan Regimen Improve Outcomes in Older Patients With AML?

Could AML Progression Be Fueled by Chemotherapy-Induced Dormancy of AML Cells?

Is MRD Status Predictive of Survival in Resistant AML?

Association Between Pretransplant Molecular MRD and Outcomes in AML

Novel Combination Results in Anticancer ‘Double Whammy’ in AML

TCT 2021: Natural Killer Cell Therapy Under Study in Selected Patients With AML

TCT 2021: CPX-351 Versus Chemotherapy for High-Risk of Secondary AML

TCT 2021: Effects of HSCT After Azacitidine Therapy for AML

Does Exposure to Occupational Pesticides Increase the Risk for AML?

TCT 2021: JSP191 With Fludarabine and Total-Body Radiation in Older Adults With AML

Eprenetapopt Plus Azacitidine Under Study in TP53-Mutant AML

Decitabine Plus Venetoclax Versus Chemotherapy Among Older Patients With AML

Why Do Some Patients With Newly Diagnosed AML Decline Treatment?

Newly Diagnosed FLT3-Mutant AML: Sorafenib Plus Chemotherapy

Gilteritinib Plus Chemotherapy for Newly Diagnosed AML

Intravenous and Subcutaneous Cytarabine for Standard Induction Therapy in AML

Quizartinib-Based Triplet Therapy for FLT3-ITD–Mutated AML

5-Year Results for CPX-351 in Older Adults With High-Risk AML

Safety Profile of Midostaurin in Older Patients With AML

Oral Azacitidine as Maintenance Therapy for Acute Myeloid Leukemia

Race Matters Significantly in AML Outcomes, Study Data Show

ASH 2020: Phase III Trial of Gilteritinib Plus Azacitidine for FLT3-Mutated AML